Primary hyperaldosteronism in the hypertensive disease

Current Hypertension Reviews

Volumn 2, Issue 1, 2006, Pages 33-40

  Fardella, Carlos E ^a   Carvajal, Cristian A ^a   Mosso, Lorena M ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Hypertension; Mineralocorticoids; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; FLUDROCORTISONE; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; METHYLDOPA; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PREDNISONE; RENIN; SODIUM; SODIUM CHLORIDE; SPIRONOLACTONE; TRIAMTERENE; UNINDEXED DRUG;

ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CHEMICAL ANALYSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GENETIC TRAIT; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPOKALEMIA; IDIOPATHIC DISEASE; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; PATHOGENESIS; POPULATION RESEARCH; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING TEST; SODIUM ABSORPTION;

EID: 33746158947     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340206775473720     Document Type: Review

References (113)

1. Takeda R, Hatakeyama H, Takeda Y, et al. Aldosterone biosynthesis and action in vascular cells. Steroids 1995;60(1):120-4. (Erratum in:Steroids 1995;60(8):540).
2. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36(4):495-500.
3. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000;141(5):1901-4.
4. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99(20):2694-701.
5. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997;138(8):3369-73.
6. Curnow KM, Tusie-Luna M, Pascoe L, et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 1991; 5:1513-1522.
7. Kawamoto T, Miysuuchi Y, Ohnishi T, et al. Cloning and expression of a cDNA for human cytochrome P450aldo as related to primary aldosteronism. Biochem Biophys Res Commun 1990; 173:309-316.
8. Ogishima T, Shibata H, Shimada H, et al. Aldosterone synthase cytochrome P450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem 1991; 266:10731-10734.
9. Kawamoto T, Mitsuuchi Y, Toda K, et al. Role of steroid 11β-hydroxylase and 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992; 89:1458-1462.
10. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11β-hydroxylase (P45011β). J Biol Chem 1989; 264:20961-20967.
11. Jackson RV, Lafferty A, Torpy DJ, Stratakis C. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 2002;970:77-88.
12. Losel R, Schultz A, Boldyreff B, Wehling M. Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 2004;69(8-9):575-8.
13. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. Am Soc Nephrol 2003;14(9): 2255-63.
14. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89-100.
15. Schmidt B, Schmieder R. Aldosterone-Induced cardiac damage: Focus on blood pressure independent effects. Am J Hypertension 2003; 16:80-86.
16. Litchfield R, Dluhy R. Primary aldosteronism. In Clinical Endocrinology Update. Ed. Wartofsky L. 1997; 241-252.
17. Ganguly A. Primary aldosteronism. Review article. N England J Med 1998; 339(25):1828-1834.
18. Ganguly A. Cellular origin of aldosteronomas. J Clin Invest 1992; 70:392-395.
19. Irony I, Kater CE, Biglieri EG, Schackleton CH. Correctable subsets of primary aldosteronism: primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-582.
20. Banks WA, Kastin AJ, Biglieri EG, Ruiz AE. Primary adrenal hyperplasia: a new subset of primary aldosteronism. J Clin Endocrinol Metab 1984; 58: 783-785.
21. Lifton RP, Dluhy RG, Powers M, et al. A chimeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265.
22. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev 2004;12(1):44-8.
23. Stowasser M, Gunasekera TG, Gordon RD Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol 2001;28(12): 1087-90.
24. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA 1965;193:200-206.
25. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 to 1975. Mayo Clin Proc 1977; 52:549-555.
26. Blumenfeld JD, Sealey JE, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877-885.
27. Komiya I, Yamada T, Aizawa T, et al. Inappropriate elevation of the aldosterone/plasma renin activity ratio in hypertensive patients whit increases of 11-deoxycorticosterone and 18-hydroxy-11-deoxycorticosterone: a subtype of essential hypertension?. Cardiology 1991; 78:99-110.
28. Gordon RD, Zlesak MD, Tunny J, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol 1993; 20:296-298.
29. Brown MA, Cramp HA, Zammit VC, Whitworth JA. Primary hyperaldosteronism: a missed diagnosis in "essential hypertensives"?. Aust NZ J Med 1996; 26 (4):533-538.
30. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141:1589-1593.
31. Bravo El. Primary aldosteronism: issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23:271-283.
32. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21(4): 315-318.
33. Fardella CE, Mosso L, Gómez-Sánchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867.
34. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14(5): 311-315.
35. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
36. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83s-85s.
37. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000;90(4): 394-400.
38. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Am J Kidney Dis 2001;37(4):699-705. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.
39. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002;48(11): 1919-23.
40. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40(6):892-6.
41. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42(2):161-5.
42. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002;15(10 Pt 1):896-902.
43. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21(11):2149-57.
44. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27(3):193-202.
45. Fardella CE, Mosso L. Prevalence of primary aldosteronism in unselected hypertensive populations. Screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86:4003-4004.
46. Kaplan N. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-54.
47. Mosso L, Fardella C, Montero J. Cautions over idiopathic aldosteronism. Lancet 2001 28;358(9278):333-334.
48. Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 1973; 37:765-775.
49. Valloton MB. Primary aldosteronism. Part I Diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1996; 45:47-52.
50. Valloton MB. Primary aldosteronism. Part II Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism. Clin Endocrinol (Oxf) 1996; 45:53-60.
51. Biglieri EG, Irony I, Kater CE. Identification and implications of new subtypes of mineralocorticoid hypertension. J Steroid Biochem 1989; 32: 199-204.
52. Ganguly A, Chavarri M, Luetscher JA, Dowdy AJ. Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethasone administration. J Clin Endocrinol Metab 1977; 44: 775-779.
53. Wenting GJ, Man In't Veld AJ, Derkx FH, Brummelen PV, Schalekamp MA. ACTH-dependent aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism. J Clin Endocrinol Metab 1978; 46:326-335.
54. Reincke M, Beuschlein F, Latronico AC, Arlt W, Chrousos GP, Allolio B. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasmas: correlation with P450scc expression. Clin Endocrinol (Oxf) 1997; 46:619-626.
55. Kem DC, Weinberger MH, Gomez-Sanchez C, Higgins JR, Kramer NJ. The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. J Lab Clin Med 1976;88:261-270.
56. Schambelan M, Brust NL, Chang BCF, Slater KL, Biglieri EG. Circadian rhythm and effect of posture on plasma aldosterone in primary aldosteronism. J Clin Endocrinol Metab 1976; 43:115-131.
57. Pascoe L, Curnow K, Slutsker L, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossover between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89:8327-8331.
58. Fallo F, Mantero F. Dexamethasone-suppressible hyperaldos-teronism. In: Biglieri EG, Melby JC, eds. Endocrine hypertension. Comprehensive endocrinology, revised series. New York: Raven Press 1990; 87-92.
59. Chu MD, Ulick SJ. Isolation and identification of 18-hydroxycortisol from the urine of patients with primary aldosteronism. J Biol Chem 1982; 257:2218-2224.
60. Ulick SJ, Chu MD, Land MJ. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue. J Biol Chem 1983; 258:5498-5502.
61. Gomez-Sanchez CE, Montgomery M, Ganguly A, et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1984; 59: 1022-1024.
62. Ulick S, Chan CK, Gill JR, et al. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1990; 71:1151-1157.
63. Gordon RD. Primary Aldosteronism. J Endocrinol Invest 18: 495-511.
64. Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene J Clin Endocrinol Metab 1998;83(9):3214-8.
65. Elphinstone MS, Gordon RD, So A, Jeske YW, Stratakis CA, Stowasser M. Clin Endocrinol (Oxf) 2004;61(6):716-23. Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKARIB) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred. Clin Endocrinol (Oxf) 2004;61(6):716-23.
66. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89(3):1045-50.
67. MacKenna TJ, Sequeira SJ, Hefferman A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-957.
68. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003; 17(4):591-605.
69. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002;57(4):457-65.
70. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40(6):897-902.
71. Leenen FH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans. Am J Med 1987;82: 969-978.
72. Oliveros-Palacios MC, Godoy-Godoy N, Colina-Chourio JA. Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein. Am J Cardiol 1991; 67: 157-161.
73. Whitworth JA, Butty J, Gordon D. Acute haemodynamic and hormonal effects of oral doxazosin in normal subjects. Clin Exp Pharmacol Physiol 1987; 14: 133-135.
74. Montero J, Soto J, Fardella J, Foradori A, Valdés G. Measurement of low levels of plasma renin activity. A methodological improvement. Rev Med Chil 1998; 126: 151-154.
75. Streeten A. Fludrocortisone suppression test. Am J Med 1979; 67:403.
76. Gill J. Hyperaldosteronism. In: Becker K ed. Principles and practice of endocrinology and metabolism, 2nd ed. Philadelphia: JB Lippincott Company 1995;716-729.
77. Litchfield WR, Dluhy RG. Primary aldosteronism. Endocrinol Metab Clin North Am 1995; 24:593-612.
78. Dluhy R, Lifton R. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60:48-51.
79. Lichfield W, New M. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82(11):3570-3573.
80. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoid - remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83:2573-2575.
81. Fardella CE, Pinto M, Mosso L, et al. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/ CYP11B2 gene. J Clin Endocrinol Metab 2001; 86:4805-4807.
82. Jonsson J, Klemm S, Tunny T, Stowasser M, Gordon R. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Bioph Res Comm 1995; 207:565-571.
83. Mosso L, Gómez-Sánchez C, Foecking M, Fardella, CE. Serum 18-hydroxycortisol in primary aldosteronism, hypertension and normotensives. Hypertension 2001; 38 (3pt2): 688-691.
84. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest 1972; 51: 1731-1742.
85. Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, Edis AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiophatic hyperaldosteronism. J Clin Endocrinol Metab 1981; 52: 195-198.
86. Mantero F, Armanini D, Boscaro M, et al. Steroids and hypertension. J Steroid Biochem Mol Biol 1991;40: 35-44.
87. Ulick S, Blumenfeld J.D, Atlas SA, Wang JZ, Vaughan ED. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993;76: 873-878.
88. Yamakita N, Mune T, Morita H, Yasuda K, Miura K, Gomez-Sanchez CE. Plasma 18-oxocortisol levels in patients with adrenocortical disorders. Clin Endocrinol 1994; 40:583-587.
89. Kenney PJ, Lee JKT. The adrenals. In Lee JKT, Sager SS, Stanley RJ, Heiken JP, eds. Computed body tomography with MRI correlation. Philadelphia. Lippincott-Raven Press 1998; 1171-1208.
90. Reznek RH, Armstrong P. Imaging in endocrinology: the adrenal gland. Clin Endocrinol 1994; 40:561-576.
91. Lopez JM, Fardella CE, Arteaga E, Michaud P, Rodriguez JA, Cruz F. Adrenal macrotumors diagnosed by computed tomography. J Endocrinol Invest 1990; 13:581-585.
92. Phillips J, Walther MM, Pezzullo J, et al. Predictive value of preoperative test in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000:85: 4526-4533.
93. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001;86(3):1066-71.
94. Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998;49(6):713-23.
95. Dunnick NR, Doppman JL, Gill JR. Localization of functional adrenal tumors by computed tomography and venous sampling. Radiology 1982; 142:429-433.
96. Young WF Jr, Stanson AW, Grants CS, Thompson GB, van Heerden JA. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913-919.
97. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004;27(5):303-10.
98. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002;10(2):97-107.
99. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 2004;17(7):597-603.
100. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285(2): H813-21.
101. Young WF, Hogan MJ, Klee GG, Grant CS, van Heerden JA. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 1990; 65:96-110.
102. Young WF Jr. Primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997; 26 (4): 801-27.
103. Guazzoni G, Montorsi R, Bergamaschi F, et al. Effectiveness and safety of laparoscopic adrenalectomy. J Urol 1994; 152:1375-1378.
104. Gagner M, Pomp A, Heniford BT, Pharand D, Lacroix A. Laparoscopic adrenalectomy: lessons from 100 consecutive procedures. Ann Surg 1997; 226: 238-246.
105. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003;17(4):591-605.
106. Young WF Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology 2003;144(6): 2208-13.
107. Young WF Jr. Primary aldosteronism - treatment options.Growth Horm IGF Res 2003;13 Suppl A:S102-8.
108. Shenker Y. Medical treatment of low-renin aldosteronism. Endocrinol Metab Clin North Am 1989; 18:415-442.
109. Hoefnagels WH, Drayer JI, Smals AG, Kloppenborg PW. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess. Clin Pharmacol Ther 1980; 27:317-323.
110. Nadler JL, Hseuth W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 1985; 60: 896-899.
111. Stimpel M, Ivens K, Wamback G, Kaufmann W. Are calcium antagonists helpful in the management of primary aldosteronism? J Cardiovasc Pharmacol 1988; 12(suppl 6): S131-S134.
112. Stewart PM. Mineralocorticoid hypertension Lancet 1999; 353:1341-1347.
113. Stowasser M, Bachmann A, Huggard P, Rossetti T, Gordon R. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000; 85: 3313-3318.